Breaking News Instant updates and real-time market news.

KBR

KBR

$16.56

1.025 (6.60%)

04:55
01/07/19
01/07
04:55
01/07/19
04:55

KBR management to meet with UBS

Meeting to be held in London, England on January 7 hosted by UBS.

  • 07

    Jan

KBR KBR
$16.56

1.025 (6.60%)

09/19/18
09/19/18
DOWNGRADE

Neutral
KBR downgraded to Neutral on potential delays at Macquarie
As previously reported, Macquarie downgraded KBR to Neutral from Outperform with a $22 price target. Analyst Sameer Rathod thinks tariffs between U.S. and China will cause uncertainty and hydrcarbon price increases, triggering delays in finalizing new US LNG projects.
09/19/18
09/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. LyondellBasell (LYB) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying consensus expectations have the company facing a "shallow trough" in petrochemical pricing leading to flat to lower consolidated EBITDA in 2019. 2. Platform Specialty Products (PAH) downgraded to Neutral from Buy at Citi with analyst Daniel Jester saying the stock could trade range-bound in the near-term as investors await the closing of the Ag transaction by late 2018 or early 2019. 3. KBR (KBR) downgraded to Neutral from Outperform at Macquarie with analyst Sameer Rathod saying he thinks tariffs between U.S. and China will cause uncertainty and hydrocarbon price increases, triggering delays in finalizing new US LNG projects. 4. OMA Airports (OMAB) downgraded to Hold from Buy at Santander. 5. Nokia (NOK) downgraded to Underperform from Neutral at Exane BNP Paribas with the firm saying they expect a miss on 6%-9% 2018 Networks margin guidance and prefers Ericsson (ERIC) given share gains, self-help measures, and cautious consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/18
MKMP
11/27/18
NO CHANGE
Target $25
MKMP
Buy
MKM Partners says Buy KBR pullback ahead of breakout
MKM Partners analyst Daniel Scott says the recent 16% pullback in KBR stock price over the past 3 weeks is a "buying opportunity", keeping his Buy rating and $25 price target on the stock. The analyst notes that while the correlation between crude oil prices and the E&C sector is high, he sees "several upcoming catalysts" potentially benefiting the stock. Specifically, Scott highlights KBR's NASA awards, SENSE program offering "over $1B alone", four LNG projects, and LOGCAP-V opportunities, with added anticipated cash infusion coming from the company's Ichthys LNG arbitration project in Australia that he expects to be used to pay down debt. The analyst also believes that KBR's valuation of 10.7-times forward earnings - below his coverage market cap average of 12.1-times - is "too compelling to ignore".
12/27/18
MKMP
12/27/18
NO CHANGE
Target $25
MKMP
Buy
KBR is 'top pick for 2019', says MKM Partners
MKM Partners analyst Daniel Scott kept his Buy rating and $25 price target on KBR, saying the stock is his "top pick for 2019". The analyst believes that the company is "closing in on its breakout earnings scenario" and also sees the valuation on the shares as "very compelling". Scott further states that KBR stock has traded down sharply recently in concert with declining crude oil prices, even though the management has decided to "pivot towards more government services and technology end markets and to reduce exposure to hydrocarbons" 3 years ago.

TODAY'S FREE FLY STORIES

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. expects cash, cash equivalents to fund operations into 4Q21 »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ECL

Ecolab

$191.28

-0.45 (-0.23%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. appoints Cassandra Choe-Juliak as acting CMO »

Affimed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Hot Stocks
Affimed N.V. plans preclinical studies for AFM28, AFM32 in 2020 »

Affimed selected two new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FB

Facebook

$197.45

2.38 (1.22%)

, BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

FB

Facebook

$197.45

2.38 (1.22%)

BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

LK

Luckin Coffee

$28.17

1.11 (4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

PTON

Peloton

$30.22

2.94 (10.78%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Recommendations
Peloton analyst commentary  »

JPMorgan reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MXL

MaxLinear

$19.84

-0.2 (-1.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Upgrade
MaxLinear rating change  »

MaxLinear upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$0.00

(0.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Conference/Events
Esterline management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:33
11/19/19
11/19
07:33
11/19/19
07:33
Hot Stocks
Affimed N.V. to initiate Phase 1/2a study of AFM24 in 1Q20 »

In October 2019, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MBRX

Moleculin Biotech

$1.04

(0.00%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Hot Stocks
Moleculin Biotech reports preliminary data from clinical trial of WP1220 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGYI

Youngevity

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Recommendations
Youngevity analyst commentary  »

Youngevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$38.84

-1.72 (-4.24%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$58.35

0.1 (0.17%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Upgrade
Ventas rating change  »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Earnings
Affimed N.V. reports Q3 EPS (EUR0.17) vs. (EUR0.19) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PGNY

Progyny

$24.89

1.095 (4.60%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CINF

Cincinnati Financial

$107.85

0.84 (0.78%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Conference/Events
Cincinnati Financial management to meet with Buckingham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TSM

TSMC

$53.41

0.12 (0.23%)

, RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

07:30
11/19/19
11/19
07:30
11/19/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSM

TSMC

$53.41

0.12 (0.23%)

RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$145.61

-0.75 (-0.51%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$414.70

7.7 (1.89%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Conference/Events
Chemed management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

VRCA

Verrica Pharmaceuticals

$14.35

-0.35 (-2.38%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Hot Stocks
Verrica Pharmaceuticals announces passing of board member Glenn Oclassen »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$103.80

2.31 (2.28%)

07:28
11/19/19
11/19
07:28
11/19/19
07:28
Recommendations
Fortinet analyst commentary  »

Fortinet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

AVGO

Broadcom

$310.95

-1.86 (-0.59%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Upgrade
Broadcom rating change  »

Broadcom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CGC

Canopy Growth

$14.21

-1.115 (-7.28%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Conference/Events
Canopy Growth management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CURR

CURE Pharmaceutical

$0.00

(0.00%)

, CNPOF

Canopy Rivers

$0.00

(0.00%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Hot Stocks
CURE Pharmaceutical appoints John Bell to board of directors »

CURE Pharmaceutical…

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CNPOF

Canopy Rivers

$0.00

(0.00%)

CGC

Canopy Growth

$14.21

-1.115 (-7.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ABY

Atlantica Yield

$0.00

(0.00%)

07:26
11/19/19
11/19
07:26
11/19/19
07:26
Conference/Events
Atlantica Yield management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.